http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107137355-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b9ed41ec71e1e3d004841f54c9eabd8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22 |
| filingDate | 2017-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48b24be868c333846cb571d0feee7e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d5cb77350fc5d675edc9fe0c82dce3 |
| publicationDate | 2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107137355-A |
| titleOfInvention | A kind of genes delivery system |
| abstract | The invention discloses the acyl RGDV (IRV) of gene nano liposome vectors Isoquinoline 3 and IRV/STAT3 siRNA genes delivery systems preparation method, IRV/STAT3 siRNA genes delivery systems are made up of in proportion liposome vectors IRV and STAT3 siRNA, nucleoprotamine, calf thymus DNA in invention, with sustained release and targeting；The present invention with lung cancer A549 cell strain for model evaluation the cell transfecting efficiency of compound, anti tumor activity in vitro, and gene silencing efficiency and cytosis mechanism in mRNA level in-site and protein level, as a result show that IRV/STAT3 siRNA genes delivery systems have more excellent antitumor activity and gene silencing efficiency than each control group.Present invention antitumor activity of IRV/STAT3 siRNA genes delivery systems using lotus S180 ascites tumors mouse as model evaluation, as a result shows 100%IRV/STAT3 siRNA groups with antitumous effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113825523-A |
| priorityDate | 2017-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 291.